Tango Therapeutics, Inc. (TNGX) is a publicly traded Healthcare sector company. As of May 21, 2026, TNGX trades at $20.87 with a market cap of $2.98B and a P/E ratio of -24.47. TNGX moved +3.69% today. Year to date, TNGX is +136.59%; over the trailing twelve months it is +918.36%. Its 52-week range spans $1.03 to $28.41. Analyst consensus is strong buy with an average price target of $30.70. Rallies surfaces TNGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tango Therapeutics Reports $379.8 M Cash Runway, Q1 Net Loss of $45.5 M: Tango Therapeutics closed Q1 2026 with $379.8 million cash runway into 2028 and logged a $45.5 million net loss ($0.32 per share) on $33.5 million R&D and $15.2 million G&A spend. Its phase 1/2 vopimetostat combinations in MTAP-deleted pancreatic and lung cancers continue, with initial data and TNG456 glioblastoma results due in 2026.
| Metric | Value |
|---|---|
| Price | $20.87 |
| Market Cap | $2.98B |
| P/E Ratio | -24.47 |
| EPS | $-0.87 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.41 |
| 52-Week Low | $1.03 |
| Volume | 45 |
| Avg Volume | 0 |
| Revenue (TTM) | $62.38M |
| Net Income | $-101.59M |
| Gross Margin | 0.00% |
10 analysts cover TNGX: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.70.